Physician profile
Roberto Benito Robles
NPI 1588659890
$4,500.66
in general payments reported to CMS, 2019-2025
28 companies · $678 in 2025
The $678 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,662 · 2020: $737 · 2021: $250 · 2022: $479 · 2023: $476 · 2024: $219 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,373.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $703.31 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $627.37 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $371.52 | 2020-2025 | Verquvo |
| Ge Healthcare | $339.08 | 2019-2023 | |
| Bard Peripheral Vascular, INC. | $327.57 | 2019-2021 | |
| Medtronic, INC. | $290.92 | 2022-2023 | Intellis Adaptivestim |
| Novartis Pharmaceuticals Corporation | $257.94 | 2019-2023 | |
| Pfizer INC. | $180.71 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $170.86 | 2019-2025 | Farxiga |
| Biotronik INC. | $159.67 | 2024-2025 | Solia, Pamira, Acticor 7 Vr-T Dx |
| Lilly USA, LLC | $146.11 | 2025 | Zepbound, Mounjaro |
| Boston Scientific Corporation | $143.34 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.58 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $112.36 | 2019-2023 | Lifevest |
| Astellas Pharma US INC | $99.99 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $83.66 | 2022 | |
| Amgen INC. | $65.47 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $60.04 | 2019 | |
| Novo Nordisk INC | $34.89 | 2025 | Wegovy |
| Glaxosmithkline, LLC. | $32.80 | 2025 | Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $29.11 | 2023-2025 | Camzyos |
| Gilead Sciences, INC. | $27.66 | 2019 | |
| Mannkind Corporation | $22.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.96 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.42 | 2025 | Gattex |
| Exact Sciences Corporation | $15.21 | 2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $14.60 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $13.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Robles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.